Pulse Biosciences Inc (PLSE)
NASDAQ: PLSEHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PLSE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.35B
- EPS (TTM)
- -$1.21
- Dividend yield
- None
- 52-week range
- 12.95 – 58.94
- Day range
- 43.84 – 46.00
- Volume / Avg
- 466.80K / 503.52K
- Beta
- —
- Shares outstanding
- 73.55M
52-week range
PLSE stock today
Pulse Biosciences (PLSE) closed at $45.55 on Nov 20, up 2.57% (+$1.14), versus the S&P 500's 3.70% decline. At this level, PLSE sits in the middle of its 52-week range of $12.95 to $58.94: 22.7% below the high, set on Nov 9, 2026 and 251.7% above the low. PLSE is up 231.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 250.1%.
Pulse Biosciences has posted a net loss over the last twelve months (EPS of -$1.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pulse Biosciences
Company profilePulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Paul Arthur LaViolette M.B.A.
- Headquarters
- Miami, FL
- Employees
- 116
- IPO year
- 2016
- Website
- pulsebiosciences.com
Financial highlights
Full financialsIn fiscal 2025, Pulse Biosciences generated $350,000 in revenue, up 0.0% from fiscal 2024. Pulse Biosciences reported a net loss of $72.8 million, compared with a loss of $53.6 million a year earlier. Gross margin was -54.0% and operating margin -21982.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $350.00K | $0 | $0 | $700.00K | $1.42M |
| Growth | — | — | -100.00% | -50.63% | — |
| Net income | $-72.78M | $-53.59M | $-42.21M | $-58.51M | $-63.66M |
| EPS (diluted) | — | — | — | — | $-2.28 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$67.67+48.56%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.29 vs $-0.35
- Surprise
- +17.14%
PLSE news
All PLSE news- Buy 3 Medical Device Stocks for a Stable Portfolio With Solid UpsideNasdaqISRG, STE, PLSE
- Pulse Bio (PLSE) Q3 2026 Earnings Call TranscriptNasdaq
- Pulse Biosciences outlines 15%-25% quarterly non-GAAP expense increase as it targets CE Mark in Q4 2027Seeking Alpha
- Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial ResultsNasdaq
- Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial ResultsBusiness Wire
- DexCom (DXCM) Surpasses Q3 Earnings and Revenue EstimatesNasdaqDXCM, PLSE
- Pulse Biosciences Consensus Price Target Increased by 15.43% to $63.58NasdaqPLSE, BF.A
- Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026Business Wire
Pulse Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRTCiRhythm Holdings Inc. | 94.72 | +0.51% | $3.18B | vs PLSE |
| NVSTEnvista Holdings Corporation | 22.91 | -1.55% | $3.67B | vs PLSE |
| ATRCAtriCure Inc. | 55.39 | +2.37% | $2.82B | vs PLSE |
| HTFLHeartflow Inc. | 46.69 | +4.62% | $4.10B | vs PLSE |
| STVNStevanato Group S.p.A. | 15.65 | -1.76% | $4.27B | vs PLSE |
| ICUIICU Medical Inc. | 172.52 | -1.84% | $4.31B | vs PLSE |
| UFPTUFP Technologies Inc. | 290.85 | -2.70% | $2.25B | vs PLSE |
| MMEDMiniMed Group Inc. | 16.01 | -1.54% | $4.50B | vs PLSE |
Indexes, lists and sector
Pulse Biosciences stock FAQ
What is Pulse Biosciences's stock price today?
PLSE last traded at $45.55 as of Nov 20, 4:00 PM EST, up 2.57% on the day. Prices are delayed at least 15 minutes.
Who is Pulse Biosciences's CEO?
Mr. Paul Arthur LaViolette M.B.A. is the chief executive officer of Pulse Biosciences Inc, which has about 116 employees.
What is the PLSE 52-week high?
The 52-week high for PLSE is $58.94 and the 52-week low is $12.95. The stock is currently 22.7% below its high.